Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
Teva Pharmaceutical Industries Ltd. (TEVA) is a global leader in generic medicines and biosimilars, delivering cost-effective healthcare solutions across 60+ countries. This dedicated news hub provides investors and professionals with verified updates on Teva’s strategic initiatives, regulatory milestones, and market developments.
Find official press releases, earnings reports, and analysis covering Teva’s core operations in generics manufacturing, innovative therapies, and active pharmaceutical ingredients (APIs). Our curated feed includes updates on FDA approvals, partnership announcements, patent developments, and sustainability initiatives impacting the pharmaceutical sector.
Bookmark this page to monitor Teva’s progress in biosimilar innovation, supply chain expansions, and responses to industry trends. All content is sourced from verified channels to support data-driven decisions in the evolving healthcare landscape.
Teva Pharmaceutical Industries Limited has achieved a legal victory as Judge Peter Wilson of the Superior Court in California ruled that Teva did not cause a public nuisance regarding opioid marketing in Orange County, Los Angeles County, Santa Clara County, and Oakland. The court also found that Teva did not engage in false or misleading advertising practices. Teva emphasizes the need for comprehensive settlements to support those affected by opioid addiction, while it remains committed to providing affordable medicines globally.
Teva Pharmaceuticals announced positive results from the Phase 3 RISE study evaluating TV-46000, a long-acting injectable risperidone formulation, aimed at treating schizophrenia. The study showed that TV-46000 significantly prolonged time to relapse and increased clinical stability compared to placebo. Among 544 randomized patients, relapse rates were dramatically lower, with only 9% at week 24 for TV-46000 users versus 28% for placebo. The safety profile was consistent with existing risperidone formulations, indicating potential enhancements in treatment options for patients suffering from this disorder.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has initiated cash tender offers totaling up to
Teva Pharmaceutical Industries Ltd. reported third-quarter 2021 revenues of $3.9 billion, down 2% year-over-year, with a GAAP EPS of $0.26 and a non-GAAP EPS of $0.59.
Key drivers included strong sales from AJOVY® and AUSTEDO®, while lower revenues from COPAXONE® impacted results. Teva reaffirmed its full-year guidance, anticipating net revenues of $16.0 - $16.4 billion and adjusted EBITDA of $4.8 - $5.1 billion. Cash flow from operations was $529 million with $795 million in free cash flow, reflecting efficient cash management.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced a collaboration with MODAG GmbH to exclusively license and develop the small molecule candidate Anle138b, targeting neurological disorders like multiple system atrophy (MSA) and Parkinson’s disease (PD). The agreement allows Teva to develop and commercialize Anle138b and related compound Sery433, following favorable Phase 1 study results. The collaboration aims to address unmet medical needs in neurodegenerative diseases, potentially impacting thousands of patients annually.
Teva Pharmaceuticals presented new analyses from the COBRA study at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The study, which included data from 99 mothers with multiple sclerosis treated with COPAXONE® (glatiramer acetate) during pregnancy and breastfeeding, found no safety concerns for infants. Specifically, there were no adverse effects on hospitalizations, antibiotic treatments, developmental delays, or growth during the first 18 months. This research addresses significant medical needs concerning treatment safety for women with MS.
U.S. federal judge dismisses AbbVie's trade secret lawsuit against Alvotech, affirming its path to market a biosimilar to Humira. This ruling, delivered on October 6, 2021, supports Alvotech's goal to provide affordable medications. Alvotech has submitted a Biologics License Application for its candidate, AVT02, which aims for FDA interchangeability designation with Humira. Teva Pharmaceuticals is Alvotech's exclusive U.S. commercialization partner for AVT02, enhancing market opportunities in a space valued at US$20 billion globally.